MedTrace Logo

Pharmacogenetics Associated With IV Ketamine

NCT04695405 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 85

Last updated 2021-08-18

No results posted yet for this study

Summary

The Canadian Rapid Treatment Center of Excellence (CRTCE) is a healthcare facility principally focused on providing best practices of intravenous ketamine treatment to adult patients suffering from treatment resistant depression. Patients who have received IV ketamine at the clinic are eligible to participate in this study where genetic biomarkers are correlated with response to IV ketamine.

Conditions

Interventions

GENETIC

Saliva Genetic Samples

Patients will provide two saliva swabs containing genetic materials.

Sponsors & Collaborators

  • Brain and Cognition Discovery Foundation

    lead OTHER

Principal Investigators

  • Joshua D Rosenblat, MD, MSc · Canadian Rapid Treatment Center of Excellence

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-21
Primary Completion
2021-07-02
Completion
2021-07-02

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04695405 on ClinicalTrials.gov